摘要：
Objective To analyze the cost-effectiveness of insulin degludec and liraglutide injection (IDegLira) compared with insulin glargine plus insulin aspart (IGar plus IAsp) in the treatment of type 2 diabetes mellitus (T2DM) based on the price of IDegLira before and after it was successfully admitted to the National Reimbursable Drug List (NRDL). Methods Cost and effectiveness parameters were obtained through systematic retrieval from PubMed, ScienceDirect, CNKI, and Wanfang database. A cost-effectiveness analysis (CEA) model was established to analyze the economics using IDegLira for T2DM patients with 1 to 5 years of medication. Results and Conclusion Before IDegLira was admitted to NRDL, its economic advantages over the IGlar plus Iasp regimen became more significant as patients’ medication time prolonged. After being admitted to NRDL, with 1 year of medication, the medical cost of IDegLira decreased by 2 853.91 yuan and the quality adjusted life years (QALY) increased by 0.120 55 than IGar plus IAsp. The sensitivity analysis was highly consistent with the results of the baseline result. After being admitted to NRDL, for patients with T2DM who have poor blood glucose control, IDegLira is absolutely an economic advantage scheme compared with IGar plus IAsp.
Sun Quan, Zhang Fang, Dong Li.
Cost-effectiveness Analysis of Insulin Degludec and Liraglutide Injection in the Treatment of Type 2 Diabetes
[J]. 亚洲社会药学, 2023, 18(3): 281-295.
Sun Quan, Zhang Fang, Dong Li.
Cost-effectiveness Analysis of Insulin Degludec and Liraglutide Injection in the Treatment of Type 2 Diabetes
[J]. Asian Journal of Social Pharmacy, 2023, 18(3): 281-295.
